These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9600596)

  • 21. [Clinicopathological study of oligodendroglioma with special reference to immunohistochemical investigation].
    Kubo O; Tajika Y; Toyama T; Tajika T; Sakairi M; Katahira M; Kitamura K
    No Shinkei Geka; 1988 Aug; 16(9):1029-35. PubMed ID: 2462693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
    Deininger MH; Weller M; Streffer J; Meyermann R
    Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.
    Kleinschmidt-DeMasters BK; Hashizumi TL; Sze CI; Lillehei KO; Shroyer AL; Shroyer KR
    J Clin Pathol; 1998 Apr; 51(4):284-93. PubMed ID: 9659240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas.
    Okada M; Yano H; Hirose Y; Nakayama N; Ohe N; Shinoda J; Iwama T
    Brain Tumor Pathol; 2011 Apr; 28(2):157-61. PubMed ID: 21312066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma.
    Lindegaard KF; Mørk SJ; Eide GE; Halvorsen TB; Hatlevoll R; Solgaard T; Dahl O; Ganz J
    J Neurosurg; 1987 Aug; 67(2):224-30. PubMed ID: 3598683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas.
    Coons SW; Johnson PC; Pearl DK
    Neurosurgery; 1997 Oct; 41(4):878-84; discussion 884-5. PubMed ID: 9316050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligodendroglioma with signet-ring cell morphology: a case report with an immunohistochemical and ultrastructural study.
    Mikami Y; Shirabe T; Hata S; Watanabe A
    Pathol Int; 1998 Feb; 48(2):144-50. PubMed ID: 9589479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofilament H immunoreaction in oligodendrogliomas as demonstrated by a new polyclonal antibody.
    Dehghani F; Maronde E; Schachenmayr W; Korf HW
    Acta Neuropathol; 2000 Aug; 100(2):122-30. PubMed ID: 10963358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of apoptosis in the prognosis of oligodendrogliomas.
    Schiffer D; Dutto A; Cavalla P; Chiò A; Migheli A; Piva R
    Neurochem Int; 1997 Aug; 31(2):245-50. PubMed ID: 9220457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas.
    Kros JM; Van Eden CG; Stefanko SZ; Waayer-Van Batenburg M; van der Kwast TH
    Cancer; 1990 Sep; 66(6):1204-12. PubMed ID: 2205356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signet-ring cell oligodendroglioma--report of two cases and discussion of the differential diagnosis.
    Kros JM; van den Brink WA; van Loon-van Luyt JJ; Stefanko SZ
    Acta Neuropathol; 1997 Jun; 93(6):638-43. PubMed ID: 9194905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligodendrogliomas in the CT/MR-era.
    Leonardi MA; Lumenta CB
    Acta Neurochir (Wien); 2001 Dec; 143(12):1195-203. PubMed ID: 11810382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of malignant features in oligodendroglial tumors.
    Saito A; Nakazato Y
    Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.
    Rodríguez-Pereira C; Suárez-Peñaranda JM; Vázquez-Salvado M; Sobrido MJ; Abraldes M; Barros F; Forteza J
    J Neurosurg Sci; 2000 Dec; 44(4):203-9; discussion 209-10. PubMed ID: 11327289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.
    Ozyigit G; Onal C; Gurkaynak M; Soylemezoglu F; Zorlu F
    J Neurooncol; 2005 Nov; 75(2):189-93. PubMed ID: 16132506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
    Park SH; Suh YL
    Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
    Machen SK; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Factors in Oligodendrogliomas: a Clinical Study of Twenty-Five Consecutive Patients.
    Atalay T; Ak H; Celik B; Gulsen I; Seckin H; Tanik N; Albayrak SB; Bavbek M
    Asian Pac J Cancer Prev; 2015; 16(13):5319-23. PubMed ID: 26225672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligodendrogliomas: the Mayo Clinic experience.
    Shaw EG; Scheithauer BW; O'Fallon JR; Tazelaar HD; Davis DH
    J Neurosurg; 1992 Mar; 76(3):428-34. PubMed ID: 1738022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors.
    Wolf HK; Buslei R; Blümcke I; Wiestler OD; Pietsch T
    Acta Neuropathol; 1997 Nov; 94(5):436-43. PubMed ID: 9386775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.